Sutcuoglu O, Ozdemir N, Yazici O. Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >/=50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer 2021;155:294-295.
PMID: 34364743